Single or repeated exposure to psychostimulants such as amphetamines and cocaine after postnatal week 3 leads to an enduring enhancement in the psychotomimetic responses elicited by a subsequent challenge of a stimulant in rodents. This behavioral sensitization phenomenon has been considered to be the neural consequences of stimulant-induced alterations in gene expression in the brain after a critical period of postnatal development. Using a differential cloning technique, RNA arbitrarily primed PCR, we have now identified from the rat neocortex a novel and developmentally regulated methamphetamine (MAP)-inducible gene mrt1 (MAP responsive transcript 1). mrt1 encodes two major types of PDZ-and PX-domains containing proteins of approximately 62 kDa in size with different carboxy termini, Mrt1a and Mrt1b. The mrt1 mRNAs for Mrt1a, mrt1a, and for Mrt1b, mrt1b, are predominantly expressed in various brain regions and the testes, respectively. Acute MAP injection upregulated mrt1b expression in the neocortex after postnatal week 3 in a D1 receptor antagonist-sensitive manner without affecting mrt1a expression. This upregulation was mimicked by another stimulant, cocaine, whereas pentobarbital and D1 antagonist failed to change the mrt1b transcript levels. Moreover, repeated daily treatment of MAP, but not MAP plus D1 antagonist, for 5 days caused an augmentation of the basal expression of mrt1b 2 and 3 weeks after the drug discontinuation. These late-developing, cocaine-crossreactive, D1 antagonist-sensitive and long-term regulations of mrt1b by MAP are similar to the pharmacological profiles of stimulant-induced behavioral sensitization, and therefore may be associated with the initiation and/or maintenance of the long-term neuronal adaptation.
Introduction
Amphetamines and cocaine have been known to elicit a variety of behavioral changes including hyperlocomotion and stereotypy by facilitating central dopaminergic transmission in experimental animals. 1 These behavioral responses are permanently augmented following a single or repeated administration of these stimulants and other dopamine agonists. 2 This sensitization or reverse tolerance phenomenon has long been believed to be a useful model of stimulantinduced psychosis or drug craving in stimulant abuse. [3] [4] [5] The long-lasting nature of the behavioral sensitization may be connected to brain plasticity as the consequence of dopamine agonist-induced molecular changes in specific regions. 6, 7 Behavioral studies using local drug infusions or lesions in various brain areas have revealed that the nucleus accumbens, striatum, ventral tegmental area (VTA), prefrontal cortex and amygdala are involved in the sensitization phenomenon. 8 Furthermore, protein synthesis inhibitors have been reported to antagonize the ability of amphetamines to cause behavioral sensitization. 2, 9, 10 Recent molecular approaches have indeed shown that attenuation of stimulant-induction of the striatal gGb1 (G-protein b1 subunit) gene 11 or of basic fibroblast growth factor 12 in the VTA blocks establishment of the enhanced behavioral responses. An important role of the prefrontal cortex in the induction of stimulant sensitization is also supported by our histochemical observations that sensitization-inducible drugs cause a selective expression of a neuroplasticity-related factor, tissue plasminogen activator mRNA, in the prelimbic cortex neurons. 13 However, the exact neuron circuits and molecular cascade essential for the behavioral sensitization await further elucidation.
The fact that dopamine agonists cause a robust and long-lasting hyperlocomotion or stereotypy sensitization after a critical period around postnatal week 3 in rodents [14] [15] [16] suggests that maturation of the specific neuronal systems could be required for the neuroadaptive phenomenon. The plausible development of functions or information processing in brain neuron circuits appears to be reflected in the results that the distribution of the brain c-Fos expression, which is a marker of neural activity, 17 following methamphetamine (MAP) or cocaine administration, changed markedly during postnatal development. [18] [19] [20] [21] The changes in the gene expression pattern were most prominent in the neocortex and/or striatum, indicating the possible implication of these areas in ontogenic development of stimulant-induced behavioral changes.
These data allow us to postulate that the neocortex and the striatum may be equipped with a neural system related to the behavioral sensitization after the critical period and that such a system should comprise stimulant-responsive molecules. To explore the hypothetical molecules that would exhibit a development-dependent response to stimulants, we have applied a differential cloning technique to the neocortex of the developing rats treated with an acute MAP injection.
Materials and methods

Animals
The present animal experiments were performed in strict accordance with the guidance of the National Institute of Neuroscience, National Center of Neurology and Psychiatry, and were approved by the Animal Investigation Committee of the Institute. Male Wistar rats (ST strain, Clea Japan, Tokyo, Japan) at postnatal days 8, 15, 23 and 50 were used. MAP hydrochloride, cocaine hydrochloride and SCH23390-hydrochloride were dissolved in physiological saline for subcutaneous (s.c.) or intraperitoneal (i.p.) injection. An ampoule solution of pentobarbital was diluted with physiological saline and injected i.p. The control animals received only the vehicle. Doses always refer to the free bases.
RNA fingerprinting
We have performed RNA fingerprinting using a 12-mer arbitrary primer (RNA arbitrarily primed PCR (RAP-PCR)) 22 to isolate the developmentally regulated neocortical transcripts responsive to MAP. Rats at PD 8 or 50 were s.c. administered 4.8 mg/kg of MAP or saline and killed by cervical dislocation 1 h later. The dose and timing of the administration of MAP were chosen because (1) the aim of this study is to obtain an insight into the initial or early step of the putative molecular cascade for behavioral sensitization, and (2) single or repeated treatment with 4.8 mg/kg of MAP has been observed to cause the sensitization phenomenon in the young adult, but not infant, rats. 19, 23 Equal amounts of total RNA prepared from the neocortex (the dorsal part of the cerebral cortex divided along the rhinal fissure) of the individual rats of every experimental group were pooled. Singlestrand cDNA was randomly primed from 0.2 mg of each pooled sample using an RNA Preamplification Kit (Life Technologies). The resulting cDNA was suspended in 10 volumes of TE buffer (pH 8.0) and 10, 5 or 2.5 ml of the suspension was used as a template for PCR using a 12-mer arbitrary primer (5 0 -CAGGTGGGACCA-3 0 ). The PCR product was separated in a 4% denaturing polyacrylamide gel containing 50% urea. The gel was stained with SYBR Green I (Molecular Probes), and the cDNA bands were visualized and analyzed by a FluorImager SI fluorescent image analyzer (Molecular Dynamics).
Quantitative RT-PCR Quantitative measurements of the RNA levels in different samples were achieved by RT-PCR coamplifying a specific target sequence with another endogenous or competitor template as the internal standard. 24 Reverse transcription was performed using 0.2 mg of neocortical total RNA from an individual animal, and the resulting cDNA was suspended in 10 volumes of TE buffer (pH 8.0). A 1 ml-aliquot of the cDNA suspension was used as a PCR template. In most experiments, 28S rRNA was employed as the internal standard to assay changes in relative expression levels of a specific transcript and coamplified with the target transcript of interest, 25, 26 because (1) 28S rRNA levels in the brain were reported not to be affected by drugs such as cannabinoid, 26 and (2) similar MAP-induced expressional changes were obtained by this quantitative method and the competitive PCR described below (data not shown). An appropriate portion (70-90%) of the added primers specific for the 28S rRNA sequence was phosphorylated at their 3 0 ends so that the target and the control amplicon will have similar amplification kinetics and their exponential phases will overlap. In the case of mrt1b amplification, 73% of the primers for 28S rRNA was phosphorylated at their 3 0 ends and PCR amplification was performed for 27 cycles (941C for 45 s, 601C for 45 s, and 721C for 45 s) (see Figure 4c) . In competitive PCR, 24 identical aliquots of cDNA are spiked with a dilution series of a competitor template that is identical to the target except for a point mutation generating a restriction site and is amplified by the same PCR primers as the target template. The resulting PCR products of the target and mutated sequence were identified by restriction analysis. The amount of the target was estimated to be the copy number of the competitor sequence per 1 mg of total RNA that leads to a 1 : 1 ratio of the target to competitor amplicons. 
Generation of Mrt1 antibodies
The Mrt1 anti-peptide antibodies were generated in rabbits. A 15-amino-acid peptide, M1-N15 (DGE-GIHPSTPHRNGG), corresponding to amino acids 5-19 of Mrt1 proteins and other 10-amino-acid peptides, M1A-C10 (ARSQQRDVAT) and M1B-C10 (CELKWR-KEEY), corresponding to the Mrt1a-specific carboxy terminus (530-539) and the Mrt1b-specific carboxy terminus (517-526), respectively, were synthesized ( Figure 3c ), crosslinked to the keyhole limpet hemocyanin and injected into rabbits to generate antisera. The resulting antisera were then purified on peptide affinity columns. In the case of the antiserum against the M1B-C10, another peptide, M1A-C12 (CELKWR-KENIFQ), corresponding to positions 517-528 of Mrt1a, was used for the absorption column.
Immunochemical analysis
Rat neocortical proteins were extracted in buffer containing 0.125%. SDS, 0.625% sodium deoxycholate, 1.25% NP-40, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA and Complete Mini (Roche). The synaptosomes and PSD fractions were prepared from rat neocortices as previously described. 27 Proteins were separated by 7.5% or 10% SDS-PAGE and transferred to Immun-Blot polyvinylidine difluoride membranes (Bio-Rad). Antibodies to SNAP-25 (Transduction Laboratories), PSD-95 (Transduction Laboratories), Kv1.4 (Upstate Biotechnology) and actin (Sigma) were applied as specified by the suppliers. Immunoblotting was quantitatively analyzed by a LumiImager chemiluminescense detector (Roche).
Statistics
For comparison between the two groups, the statistical significance of the data was evaluated using the two-tailed Student's t-test. Statistical differences among more than three groups were estimated by a one-way analysis of variance (ANOVA) followed by the Fisher PLSD or the Scheffé post hoc test for the quantitative analysis of the gene expression, or by the Kruskal-Wallis test followed by Dunnet's multiple comparison test for behavioral rating.
Nucleotide sequences
The DDBJ/GenBank/EMBL accession numbers for primary nucleotide sequence of mrt1 are AB010245, AB051852 and AB051816 (see also the legend for Figure 2 ).
Results
Cloning of a novel rat gene mrt1 encoding PDZ-PX proteins A series of RNA fingerprintings have detected PCR products of 0.6 kb that are upregulated and unchanged in the adult and infant rat neocortex, respectively, 1 h after MAP injection (4.8 mg/kg) ( Figure 1a ). Cloning and sequence analysis of their corresponding cDNAs have identified a novel rat gene mrt1 (MAP-responsive transcript 1) encoding PDZand PX-domains containing proteins (Figures 2a and  b) . Although a genomic cosmid clone F25H2 of Caenorhabditis elegans (accession number ¼ Z79754) contains a gene F25H2.2 closely related to rat mrt1, its predicted protein product lacks a glycine-rich motif found at the amino terminus of the Mrt1 proteins (the amino acid identity is 43%).
The mrt1 transcripts consist of two major types of splicing variants with different open reading frames (ORFs), and they were detected as two distinct bands in the Northern blot (Figures 1b and c) . The transcripts in the lower band are predicted to encode a protein with a short hydrophilic carboxy terminus (alpha-isoform of Mrt1, Mrt1a), while the other isoform (beta-isoform of Mrt1, Mrt1b) encoded by those in the upper band lacks this structure ( Figures  2a and b) . The mrt1 mRNAs for Mrt1b and Mrt1a displayed a predominant expression in various brain areas and the testes, respectively (Figure 1d ).
Mrt1a and Mrt1b proteins as revealed by immunological analysis
As shown in Figure 3a , we generated three types of rabbit polyclonal antibodies against the N-terminal Mrt1 residues 5-19 common to Mrt1a and Mrt1b (M1-N15, Figure 2a )(anti-pan-Mrt1 antibody), the Mrt1a-specific C-terminal amino acids 530-539 (M1A-C10, Figure 3c )(anti-Mrt1a) and the Mrt1b-specific Cterminal residues 517-526 (M1B-C10, Figure  3c )(anti-Mrt1b).
The Mrt1 proteins were detected as a band of 62 kDa by each antibody in the Western blot of the neocortical extract obtained from the adult and infant rats ( Figure 3b ). The preimmune sera or the presence of either antigen with the corresponding antibody detected no immunoreactivity at the size of 62 kDa (data not shown). Although the M1B-C10 peptide of Mrt1b contains the amino-acid sequence found in the M1A-C12 peptide of Mrt1a, the band of 62 kDa recognized by the affinity-purified anti-Mrt1b antibody disappeared in the presence of M1B-C10, but not M1A-C12, antigen ( Figure 3d ). These results indicate that the antibody specifically recognizes the Mrt1b protein (Figure 3d) .
A subcellular fractionation study using these antibodies revealed that the Mrt1b-like immunoreactivity was enriched in the synaptosomal fraction but undetectable in the detergent-treated postsynaptic density (PSD) of the adult neocortex ( Figure 3e ). This fractionation pattern is similar to those of presynaptic marker proteins, SNAP-25 28 and Kv 1.4, 29 but different from that of a postsynaptic marker, PSD-95, 30 whereas there was no substantial Mrt1a-like immunoreactivity in the synaptosomes and PSD.
Differential effects of acute MAP on expression of mrt1a and mrt1b transcripts in the neocortex of adult rats The effects of various drugs on the cerebral mrt1 expression were examined by variant-specific and quantitative RT-PCR methods. Variant-specific PCR amplification was performed using the primer sets shown in Figure 4a . As indicated in Figure 4b , introduction of a single mismatched nucleotide to the 3 0 region of the upper primer for mrt1a, which recognizes the splicing boundary, enabled the selective amplification of the mrt1a-specific 126-bp PCR product without the nonspecific 905-bp PCR product. For relative quantification, a coamplification RT-PCR method with 28S ribosomal RNA (rRNA) as an internal control was successfully applied using the specific primers for the 28S rRNA sequence a portion of which was phosphorylated at their 3' ends ( Figure  4c ). In some quantification experiments, mRNA expression levels were also estimated by a competitive RT-PCR method.
The PCR amplification of mrt1 mRNAs under these conditions revealed that only the brain-preferring splicing variants for Mrt1b were responsive to MAP in the adult rat neocortex (Figure 4d ). After an acute s.c. administration of MAP (4.8 mg/kg), the levels of the mrt1b mRNA in the neocortex of 50-day-old rats rapidly increased, peaked at 1 h and returned to the saline-treated control levels within 24-h post-injection (Figure 5a ). Therefore, we routinely measured the mrt1b mRNA 1 h after an acute injection of MAP.
Effects of acute MAP on expression of mrt1b transcripts in the neocortex of the developing rats In the neocortical tissues of developing rats, MAP produced an augmentation in the total amount of the mrt1a and mrt1b transcripts at PD 23 and 50, but not at PD 8 and 14 ( Figure 5b ). These results, obtained by quantitative assays, confirmed the differential responses of the mrt1 transcripts to MAP between PD 8 and 50 revealed by the RAP-PCR analysis. The specific amplification of the mrt1b mRNA also reproduced the developmental changes in the (Figure 2a ) to Mrt1a and Mrt1b (a-pan-Mrt1). Isoform-specific antibodies were also generated against a C-terminal peptide M1A-C10 specific to Mrt1a (a-Mrt1a) and against a C-terminal peptide M1B-C10 specific to the Mrt1b (a-Mrt1b) (see also panel c). G, PDZ and PX indicate the glycine-rich, PDZ and PX domains found in Mrt1 proteins, respectively. (b) Western blot of 25 mg protein samples extracted from the infant (PD 8) or adult (PD 50) rat neocortex. The anti-pan-Mrt1 antibody recognized a 62 kDa protein in these samples as indicated by an arrowhead. Preabsorbtion of anti-pan-Mrt1 antibody with the corresponding immunogenic peptide blocked the immunorecognition (data not shown). (c) Amino-acid sequences of the different C-termini of Mrt1a and Mrt1b corresponding to the peptides used for generation of isoform-specific anti-Mrt1 antibodies. The common sequence to Mrt1a and Mrt1b is underlined. (d) Characterization of Mrt1b-specific antibody. The immunorecognition by the anti-Mrt1b antibody was blocked by preabsorption using the Mrt1b-specific immunogenic peptide M1B-C10, but not by the Mrt1a-specific immunogenic peptide M1A-C12. Each blot containing 25 mg of neocortical extract from infant rats was re-probed by anti-actin antibody following the reaction with anti-Mrt1 antibodies. The protein band of 62 kDa recognized by the anti-Mrt1a antibody disappeared after preincubation with M1A-C12, but not M1B-C10, peptide (data not shown). (e) Subcellular localization of Mrt1 proteins in the neocortical tissues. Mrt1b or pan-Mrt1 immunoreactivity was predominantly enriched in the synaptosomes but undetectable in the PSD isolated by treating the synaptosomes once with 0.5% Triton X-100. Similarly, presynaptic marker proteins, SNAP-25 and Kv 1.4, were recognized by their antibodies in the synaptosomes but not in the PSDs. In contrast, there was no Mrt1a-specific immunoreactivity in the synaptosomal or PSD fraction.
MAP-induced increase in the c-fos gene expression was seen from PD 8 to 50 in various brain areas (data not shown).
Effects of acute administration of various drugs on expression of mrt1b transcripts in the neocortex of adult rats
In the adult period (PD 50), acute MAP application at the low (1.6 mg/kg: saline 10078%, MAP 15477%*, n ¼ 6, *Po0.05 as compared to saline controls) and moderate (4.8 mg/kg: see Figures 3d and 4a ) doses cause different behavioral abnormalities, hyperlocomotion and stereotypy, respectively, but a similar magnitude of increase in the neocortical mrt1b expression. These increases in mRNA expression appear to be translated into corresponding changes in protein levels because the neocortical expression of Mrt1 detected using anti-pan-Mrt1 antibody was augmented 3 h after acute administration of MAP (1.6 mg/kg, s.c.) (saline 10076%, MAP 141716%*, n ¼ 6, *Po0.05 as compared to saline controls). The neocortical levels of the mrt1b mRNA were elevated by another sensitization-inducible dopamine agonist cocaine (30 mg/kg, s.c.) (Figure 5c ), but not by an anesthetic with abuse potential, pentobarbital (40 mg/kg, intraperitoneally (i.p.)), and a selective D1 dopamine receptor antagonist, SCH23390 (R( þ )-7-chloro-8-hydroxy-3-methyl-1-phenyl-2, 3, 4, 5-tetrahydro-1H-3-benzazepine, 0.5 mg/kg, s.c) (Figure 5c ) which are not capable of producing a behavioral sensitization to amphetamines. 2, 8 The D1 receptor antagonist (0.5 mg/kg, i.p.) given 30 min before MAP injection completely attenuated the increasing effects of the acute MAP on the mrt1b mRNA levels (Figure 5d ).
Effects of repeated treatment with MAP on neocortical mrt1 expression in the adult rats Repeated treatment of adult rats with MAP for 5 days (4.0 mg/kg, s.c., once a day), which has been reported to elicit behavioral sensitization to stimulant in the rat, 23 resulted in a lasting increase in the basal expression of the Mrt1b-related variants on 14 (Figures 6a and b) and 21 (and data not shown) days of withdrawal. This enduring upregulation of the mrt1b mRNA was not observed in the rats coadministered with MAP plus SCH23390 (Figure  6d ), indicating that the lasting change may depend upon a D1-mediated transient elevation of the gene expression following acute MAP.
Discussion
In the present study, we have isolated by an RNA fingerprinting technique a novel development-and MAP-regulated gene, mrt1, from the rat neocortex. MAP upregulated mrt1b, but not mrt1a, type transcripts after the weaning in a D1 receptor antagonist reversible fashion. Another psychostimulant acting as an indirect dopamine agonist, cocaine, but not an anesthetic, pentobarbital, also causes an increased expression of mrt1b. We further demonstrate that basal expression of neocortical mrt1b transcripts remains increased even long after the discontinuation of repeated MAP treatment in the adult period while this increase is eliminated by coadministration of the D1 antagonist with MAP in each treatment. These pharmacological profiles of mrt1b responses suggest that mrt1b-encoded proteins appear to be associated with initiation and/or sustenance of developmentdependent and D1 receptor-mediated enduring changes after stimulant treatment such as behavioral sensitization.
The predicted amino acid sequence for analysis of the cloned mrt1 cDNA indicates that mrt1 encodes two major types of novel proteins with a PDZ-and a PX-domain, Mrt1a and Mrt1b. No protein with a PDZdomain followed by a PX-domain has so far been identified. The two different deduced open reading frames seem to be valid, because (1) the anti-pan-Mrt1 antibody generated against the predicted sequence recognized a 62 kDa protein which is around the expected molecular size of an Mrt1 protein, and (2) the preabsorption test in immunoblot analysis using anti-Mrt1a and anti-Mrt1b antibody and their corresponding immunogenic peptides revealed that the respective isoform-specific sequence in the ORFs were indeed detected as a 62 kDa protein band in the rat brain samples. Predominant expression of Mrt1b in synaptosomal, but not PSD, fraction is similar to those of presynaptic proteins, suggesting that Mrt1b may be associated with presynaptic organizations, although PDZ proteins have previously been reported to be localized at the postsynaptic site. 31 However, Mrt1a-like immunoreactivity is sparse in the synaptosomal fraction. Distinct distributions of Mrt1a and Mrt1b indicate the possible differences in physiological functions of these isoforms.
Also, the respective transcripts for Mrt1a and Mrt1b have contrasting patterns of distribution and responses to MAP. mrt1b and mrt1a mRNA displayed a brain-and testis-selective expression, respectively. MAP causes an increase in the levels of mrt1b without affecting mrt1a expression in the adult rat neocortex. Our observation that 1.6 and 4.8 mg/kg of MAP produced different behavioral changes but a similar magnitude of elevation of the mrt1b transcript seems to deny the possibility that the augmented expression of mrt1b is solely related to the acute and specific motor effects of MAP. It is unlikely that the mrt1b upregulation could be a non-specific phenomenon or associated with a general signaling pathway to addiction, because another drug of abuse potential, pentobarbital, does not affect mrt1b expression.
The complete attenuation by D1 antagonist of acute MAP-induced upregulation of mrt1b and cocaineinduction of the transcript expression suggest that the transient mrt1b induction may be located downstream in the putative cascade following dopamine D1 receptor stimulation. The protein kinase A is shown to be activated by these stimulants through the G i -coupled dopamine receptor; kinase A then phosphorylates the cyclic-AMP response-element-binding protein (CREB) followed by immediate induction of numerous early genes including Fos family transcription factors. 6, 7 From these data together with the early induction of mrt1b mRNA, we can extrapolate that the mrt1 gene could be under the control of CREB. Ontogenic development of mrt1 response to MAP might also depend upon that of these transcriptional activators because neuronal activity-dependent plasticity during postnatal neocortical development has been demonstrated to be correlated with CRE activation using transgenic mice carrying a CRE-lacZ reporter. 32 The exact mechanisms underlying the selective induction of mrt1b transcripts by MAP are unknown. mrt1a and mrt1b expression would be regulated by distinct molecular pathways specific to the respective production or degradation processes. A slight but not significant reduction in the mrt1a mRNA levels by MAP could result from the possibility that MAPinduced alterations in neurotransmitter or other signaling systems may not produce a substantial influence on the splicing acceptor site selection for mrt1a variants. It cannot be totally excluded that MAP or certain molecular changes following MAP injection might attenuate an mrt1b-specific degradation process. Interestingly, another psychoactive substance, ethanol, has been reported to cause selective changes in the expression of exon 5-containing Nmethyl-D-aspartate NR1 splice variants in mouse fetal cortical neurons although the regulatory signals for the differential effects have not yet been identified. 33 Repeated MAP treatment results in an increase in the basal levels of the neocortical mrt1b mRNA at 2 and 3 weeks of withdrawal while a rapid and transient augmentation of the gene expression occurs after acute MAP administration. These data indicate that the repeated MAP-induced increase might be a long-lasting phenomenon and regulation of mrt1 transcription could be modified during or after the repeated treatment. The plausible modification would be associated with the exclusive structure of Mrt1 proteins although the precise functions of the mrt1 protein products are still unclear. A PDZ-and PXdomain contained in Mrt1 proteins have been reported to mediate protein-protein interactions. It is generally accepted that synapse-associated proteins containing PDZ domains create the basic scaffold upon which membrane-associated protein complexes including receptors, ion channels, cellular adhesion molecules, etc., are organized. 34 Such a molecular scaffold has been considered to play an important role in not only synaptic formation but also synaptic rearrangement. The PX domain is a recently identified motif and has been demonstrated to function as a target of the SH (src homology) 3 domain that is also implicated in synaptic organization or reorganization. Because the Mrt1b isoform is concentrated in the brain synaptosomes, this type of mrt1 product may participate in the remodeling of the synaptic machinery for neuroadaptive changes following stimulant administration through its function as a molecular scaffold. 35 The consequential molecular and structural modifications of the synapses or other neural architectures might in turn cause a persistent change in the regulation of the mrt1 gene that is a long-lasting augmentation of the basal expression of mrt1 mRNA. In fact, amphetamine treatment has been documented to alter the morphology of the cortical and accumbal neurons. 36, 37 Upregulation following repeated stimulant treatment has also been observed in the cerebral basal expression of several molecules including DFosB, 38, 39 
NAC1
40 and basic fibroblast growth factor (bFGF).
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Because DFosB accumulates with repeated stimulant administration and then endures for a month or two as it gradually comes down to baseline, 38 and because NAC1 shows tolerance with repeated injection of stimulant but then increases during withdrawal, there remain, at least, two possibilities that either temporal pattern of expression would lead to the increased levels of mrt1b transcripts after repeated MAP. Recently, Cdk5 has been identified as a downstream target gene of a unique transcription factor of the Fos family, DFos.
39 Cdk5 inhibitors enhanced behavioral effects of repeated cocaine injection. Furthermore, increased Cdk5-dependent phosphorylation of DARPP-32 attenuated the signaling via the D1 receptor and PKA. 41 Similarly, a brain POZ/BTB protein NAC1, which is upregulated in the nucleus accumbens 3 weeks after chronic cocaine self-administration, can prevent cocaine-induced sensitization in the rat. These experiments suggest that a DFosBCdk5 cascade and NAC1 may mediate a homeostatic negative feedback response to minimize the behavioral impact of subsequent stimulant administration. [39] [40] [41] In contrast to Cdk5 and NAC1, bFGF may play a significant role in establishing and/or sustaining sensitization because (1) the development of sensitization to amphetamine was blocked when the stimulant injections were preceded by infusions of a neutralizing antibody against bFGF into the VTA, 12 and (2) repeated coadministration of a nonselective glutamate receptor antagonist with amphetamine produced neither sensitization nor elevated bFGF expression. 42 To investigate the possible relation of Mrt1b with DFosB, Cdk5, NAC1 or bFGF would provide a clue to the molecular basis for an increase in mrt1b mRNA levels after repeated MAP.
The late-developing, cocaine-crossreactive, D1 antagonist-sensitive and long-term nature of MAPinduced changes in mrt1b expression seems to meet with those of behavioral sensitization. These features, together with the fact that mrt1b expression is almost equally augmented by a dose of either 1.6 or 4.8 mg/kg of MAP leading to behavioral sensitization, suggest that the upregulation of mrt1b expression by a single dose of stimulant is most likely to be an early molecular signaling for the establishment or compensation of the stimulant sensitization. The presumed contribution of mrt1 is supported by the lack of response of the gene to a challenge dose of MAP or cocaine in the neocortex of the behaviorally sensitized rats (unpublished data). The enduring alterations in the cerebral mrt1b expression after repeated MAP might also be involved in the mechanisms sustaining behavioral sensitization. The hypothetical roles of mrt1b and Mrt1b in the behavioral adaptation should further be evaluated by experiments manipulating overexpression or reduced expression of these molecules as demonstrated in gGb1 11 and bFGF. 12 In conclusion, the present findings have provided evidence that an acute stimulant causes a D1 receptor antagonist-sensitive and neocortical upregulation of a brain-preferable type transcript of a novel rat gene mrt1, mrt1b, that encodes a PDZ-PX protein. The mrt1 gene is the first example of stimulant-inducible genes in that the induction depends upon postnatal development and apparently occurs after the critical period of behavioral sensitization. These unique profiles suggest that a neocortical neuronal system affected by psychostimulants, which could functionally maturate around the weaning period, may contain a signal cascade including mrt1b or Mrt1b. Further investigation of the physiological and pathophysiological functions, neuroanatomical features and related molecules of basal and stimulant-induced expression of mrt1b and Mrt1b, and their postnatal development will help to elucidate the specific neuron circuits and molecular cascade to stimulantinduced neural plasticity and mental dysfunctions. We have currently searched for human homologs of mrt1 gene to clarify the possible involvement of modifications of mrt1 gene and/or its protein products in psychiatric disorders.
